2
|
Abderrahmani A, Yengo L, Caiazzo R, Canouil M, Cauchi S, Raverdy V, Plaisance V, Pawlowski V, Lobbens S, Maillet J, Rolland L, Boutry R, Queniat G, Kwapich M, Tenenbaum M, Bricambert J, Saussenthaler S, Anthony E, Jha P, Derop J, Sand O, Rabearivelo I, Leloire A, Pigeyre M, Daujat-Chavanieu M, Gerbal-Chaloin S, Dayeh T, Lassailly G, Mathurin P, Staels B, Auwerx J, Schürmann A, Postic C, Schafmayer C, Hampe J, Bonnefond A, Pattou F, Froguel P. Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. Diabetes 2018; 67:1310-1321. [PMID: 29728363 DOI: 10.2337/db17-1539] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 04/26/2018] [Indexed: 12/17/2022]
Abstract
In type 2 diabetes (T2D), hepatic insulin resistance is strongly associated with nonalcoholic fatty liver disease (NAFLD). In this study, we hypothesized that the DNA methylome of livers from patients with T2D compared with livers of individuals with normal plasma glucose levels can unveil some mechanism of hepatic insulin resistance that could link to NAFLD. Using DNA methylome and transcriptome analyses of livers from obese individuals, we found that hypomethylation at a CpG site in PDGFA (encoding platelet-derived growth factor α) and PDGFA overexpression are both associated with increased T2D risk, hyperinsulinemia, increased insulin resistance, and increased steatohepatitis risk. Genetic risk score studies and human cell modeling pointed to a causative effect of high insulin levels on PDGFA CpG site hypomethylation, PDGFA overexpression, and increased PDGF-AA secretion from the liver. We found that PDGF-AA secretion further stimulates its own expression through protein kinase C activity and contributes to insulin resistance through decreased expression of insulin receptor substrate 1 and of insulin receptor. Importantly, hepatocyte insulin sensitivity can be restored by PDGF-AA-blocking antibodies, PDGF receptor inhibitors, and by metformin, opening therapeutic avenues. Therefore, in the liver of obese patients with T2D, the increased PDGF-AA signaling contributes to insulin resistance, opening new therapeutic avenues against T2D and possibly NAFLD.
Collapse
Affiliation(s)
- Amar Abderrahmani
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
- Section of Genomics of Common Disease, Department of Medicine, Imperial College London, London, U.K
| | - Loïc Yengo
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Robert Caiazzo
- University Lille, INSERM, CHU Lille, U1190 - European Genomic Institute for Diabetes, Lille, France
| | - Mickaël Canouil
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Stéphane Cauchi
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Violeta Raverdy
- University Lille, INSERM, CHU Lille, U1190 - European Genomic Institute for Diabetes, Lille, France
| | - Valérie Plaisance
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Valérie Pawlowski
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Stéphane Lobbens
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Julie Maillet
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Laure Rolland
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Raphael Boutry
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Gurvan Queniat
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Maxime Kwapich
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Mathie Tenenbaum
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Julien Bricambert
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Sophie Saussenthaler
- Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, and German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Elodie Anthony
- Inserm U1016, Institut Cochin, Centre National de la Recherche Scientifique UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Pooja Jha
- Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Julien Derop
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Olivier Sand
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Iandry Rabearivelo
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Audrey Leloire
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
| | - Marie Pigeyre
- University Lille, INSERM, CHU Lille, U1190 - European Genomic Institute for Diabetes, Lille, France
| | - Martine Daujat-Chavanieu
- INSERM U1183, University Montpellier, Institute for Regenerative Medicine and Biotherapy, CHU Montpellier, France
| | - Sabine Gerbal-Chaloin
- INSERM U1183, University Montpellier, Institute for Regenerative Medicine and Biotherapy, CHU Montpellier, France
| | - Tasnim Dayeh
- Department of Clinical Science, Skane University Hospital Malmö, Malmö, Sweden
| | - Guillaume Lassailly
- University Lille, INSERM, CHU Lille, U995 - Lille Inflammation Research International Center, Lille, France
| | - Philippe Mathurin
- University Lille, INSERM, CHU Lille, U995 - Lille Inflammation Research International Center, Lille, France
| | - Bart Staels
- University Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011- European Genomic Institute for Diabetes, Lille, France
| | - Johan Auwerx
- Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Annette Schürmann
- Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, and German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Catherine Postic
- Inserm U1016, Institut Cochin, Centre National de la Recherche Scientifique UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Clemens Schafmayer
- Department of Visceral and Thoracic Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Jochen Hampe
- Medical Department 1, Technische Universität Dresden, Dresden, Germany
| | - Amélie Bonnefond
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
- Section of Genomics of Common Disease, Department of Medicine, Imperial College London, London, U.K
| | - François Pattou
- University Lille, INSERM, CHU Lille, U1190 - European Genomic Institute for Diabetes, Lille, France
| | - Philippe Froguel
- University Lille, Centre National de la Recherche Scientifique, Institut Pasteur de Lille, UMR 8199 - European Genomic Institute for Diabetes, Lille, France
- Section of Genomics of Common Disease, Department of Medicine, Imperial College London, London, U.K
| |
Collapse
|
7
|
Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2011; 131:193-200. [PMID: 21805476 DOI: 10.1002/ijc.26338] [Citation(s) in RCA: 116] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Accepted: 06/27/2011] [Indexed: 02/06/2023]
Abstract
Initial studies have indicated diabetes and obesity to be risk factors for hepatocellular carcinoma; but the association between other metabolic risk factors and primary liver cancer (PLC) has not been investigated. The metabolic syndrome and cancer project (Me-Can) includes cohorts from Norway, Austria and Sweden with data on 578,700 subjects. We used Cox proportional hazard models to calculate relative risks (RRs) of PLC by body mass index (BMI), blood pressure and plasma levels of glucose, cholesterol and triglycerides as continuous standardized variables (z-score with mean = 0 and standard deviation (SD) = 1) and their standardized sum of metabolic syndrome (MetS) z-score. RRs were corrected for random error in measurements. During an average follow-up of 12.0 years (SD = 7.8), 266 PLCs were diagnosed among cohort members. RR of liver cancer per unit increment of z-score adjusted for age, smoking status and BMI and stratified by birth year, sex and sub-cohorts, was for BMI 1.39 (95% confidence interval (CI) 1.24-1.58), mid blood pressure 2.08 (0.95-4.73), blood glucose 2.13 (1.55-2.94) cholesterol 0.62 (0.51-0.76) and serum triglycerides 0.85 (0.65-1.10). The RR per one unit increment of the MetS z-score was 1.35 (1.12-1.61). BMI, glucose and a composite MetS score were positively and cholesterol negatively associated with risk of liver cancer.
Collapse
Affiliation(s)
- Wegene Borena
- Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54:463-71. [PMID: 21538440 PMCID: PMC4141525 DOI: 10.1002/hep.24397] [Citation(s) in RCA: 417] [Impact Index Per Article: 32.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Accepted: 04/16/2011] [Indexed: 12/11/2022]
Abstract
UNLABELLED Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the United States. Metabolic syndrome is recognized as a risk factor for HCC and a postulated one for ICC. The magnitude of risk, however, has not been investigated on a population level in the United States. We therefore examined the association between metabolic syndrome and the development of these cancers. All persons diagnosed with HCC and ICC between 1993 and 2005 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For comparison, a 5% sample of individuals residing in the same regions as the SEER registries of the cases was selected. The prevalence of metabolic syndrome as defined by the U.S. National Cholesterol Education Program Adult Treatment Panel III criteria, and other risk factors for HCC (hepatitis B virus, hepatitis C virus, alcoholic liver disease, liver cirrhosis, biliary cirrhosis, hemochromatosis, Wilson's disease) and ICC (biliary cirrhosis, cholangitis, cholelithiasis, choledochal cysts, hepatitis B virus, hepatitis C virus, alcoholic liver disease, cirrhosis, inflammatory bowel disease) were compared among persons who developed cancer and those who did not. Logistic regression was used to calculate odds ratios and 95% confidence intervals. The inclusion criteria were met by 3649 HCC cases, 743 ICC cases, and 195,953 comparison persons. Metabolic syndrome was significantly more common among persons who developed HCC (37.1%) and ICC (29.7%) than the comparison group (17.1%, P<0.0001). In adjusted multiple logistic regression analyses, metabolic syndrome remained significantly associated with increased risk of HCC (odds ratio=2.13; 95% confidence interval=1.96-2.31, P<0.0001) and ICC (odds ratio=1.56; 95% confidence interval=1.32-1.83, P<0.0001). CONCLUSION Metabolic syndrome is a significant risk factor for development of HCC and ICC in the general U.S. population.
Collapse
Affiliation(s)
- Tania M. Welzel
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA,Klinikum der J.W. Goethe-Universität Frankfurt am Main, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Barry I. Graubard
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | - Stefan Zeuzem
- Klinikum der J.W. Goethe-Universität Frankfurt am Main, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Hashem B. El-Serag
- Sections of Health Services Research and Gastroenterology, Michael E. Debakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas
| | - Jessica A. Davila
- Sections of Health Services Research and Gastroenterology, Michael E. Debakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas
| | - Katherine A. McGlynn
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| |
Collapse
|